Explore

Trendline Trendline
FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls
Trendline Trendline
API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'
Trendline Trendline
Eli Lilly Faces Price Competition After FDA Approval of Oral Obesity Drug

Eli Lilly Faces Price Competition After FDA Approval of Oral Obesity Drug

Eli Lilly Faces Price Competition After FDA Approval of Oral Obesity Drug
Trendline Trendline
Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation
Trendline Trendline
Kessler Topaz Meltzer Check, LLP Urges Soleno Therapeutics Investors to Join Class Action Lawsuit

Kessler Topaz Meltzer Check, LLP Urges Soleno Therapeutics Investors to Join Class Action Lawsuit

Kessler Topaz Meltzer Check, LLP Urges Soleno Therapeutics Investors to Join Class Action Lawsuit
Trendline Trendline
API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development
Trendline Trendline
Faruqi Faruqi, LLP Alerts Ultragenyx Pharmaceutical Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Ultragenyx Pharmaceutical Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Ultragenyx Pharmaceutical Investors of Securities Class Action Deadline
Trendline Trendline
Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements
Trendline Trendline
Viking and Structure Therapeutics Become Key Targets in Metabolic Health Sector

Viking and Structure Therapeutics Become Key Targets in Metabolic Health Sector

Viking and Structure Therapeutics Become Key Targets in Metabolic Health Sector
Trendline Trendline
Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans

Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans

Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans
Trendline Trendline
GATC Health's AI Platform Reduces Drug Development Costs with In Silico Models

GATC Health's AI Platform Reduces Drug Development Costs with In Silico Models

GATC Health's AI Platform Reduces Drug Development Costs with In Silico Models
Trendline Trendline
Pharma M Activity Surges with Record Highs Anticipated in 2026

Pharma M Activity Surges with Record Highs Anticipated in 2026

Pharma M Activity Surges with Record Highs Anticipated in 2026